Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
Gossamer Bio (GOSS) Stock Price & Analysis
595 Followers
GOSS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $1.88
Previous Close$0.74
Volume350.02K
Average Volume (3M)1.74M
Market Cap
$165.16M
Enterprise Value-$115.95M
Total Cash (Recent Filing)$296.43M
Total Debt (Recent Filing)$12.57M
Price to Earnings (P/E)-0.7
Beta1.71
Next Earnings
Aug 06, 2024EPS Estimate
$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding226,218,652
10 Day Avg. Volume2,904,177
30 Day Avg. Volume1,742,883
Standard Deviation0.24
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)2.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.77
Forecast
1Y Price Target
$7.25Price Target Upside893.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Gossamer Bio News
PremiumCompany Announcements
Gossamer Bio Forms Major Alliance with Chiesi FarmaceuticiBulls Say, Bears Say
Bulls Say
Financial HealthImmediate development reimbursement payment of $160mn improves GOSS’ capital position.
Regulatory AdvancementChiesi's experience with the EMA is anticipated to benefit GOSS in navigating regulatory pathways.
Strategic CollaborationAnnounces transformational collaboration to develop and commercialize seralutinib for the treatment of pulmonary arterial hypertension and associated diseases.
Bears Say
Clinical Trial RiskPH-ILD study still likely to be perceived as high-risk with data still years out.
Collaboration AgreementDeal comes with meaningful dilution of seralutinib economics, with a 50/50 profit split in the US, and mid-teens royalty outside the US.
Stock PerformanceLimited catalyst flow for Gossamer over the next 12 months may affect investor perception and stock performance.
---
Ownership Overview
11.38% Insiders
13.83% Mutual Funds
64.18% Other Institutional Investors
10.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.45 and its highest was $1.88 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Currently, no data Available
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is Aug 06, 2024 which is in 82 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on May 07, 2024. The company reported -$0.19 earnings per share for the quarter, the consensus estimate of -$0.19 by $0.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is $0.28.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 226,218,660 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of -$0.19 in its last earnings report, expectations of -$0.19. Following the earnings report the stock price went up 4.11%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Among the largest hedge funds holding Gossamer Bio Inc’s share is Farallon Capital Management, L.L.C.. It holds Gossamer Bio Inc’s shares valued at 7M.
---
Gossamer Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (893.01% Upside)
$7.25 (893.01% Upside)
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
---
GOSS Stock 12 Month Forecast
Average Price Target
$7.25
▲(893.01% Upside)
Technical Analysis
Leap Therapeutics
―
Eton Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Apellis Pharmaceuticals
―
Best Analysts Covering GOSS
1 Year
1 Year Success Rate
7/24 ratings generated profit
1 Year Average Return
-32.60%
reiterated a buy rating 8 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 29.17% of your transactions generating a profit, with an average return of -32.60% per trade.
---